The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.
The U.S. Food and Drug Administration (FDA) created a major media stir last week when it announced the approval of suzetrigine (brand name Journavx), a unique new non-opioid, non-addictive drug for ...